Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection.

Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer.

Translational Genomics Research Institute has found macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer, osteoporosis and osteolysis.

Tocris Cookson Ltd., Helmholtz Zentrum fur Infektionsforschung GmbH and University of Lübeck have described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands covalently bonded to non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) targeting moiety through linker reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Just a few days after the U.S. Congressional Research Service issued a report suggesting ways Congress could resolve the unanswered questions about patent listings in the FDA’s Orange Book, the FTC sent a second round of warning letters to eight biopharma companies and their subsidiaries, citing the listing of device patents for combination products.

A Jaguahr Therapeutics Pte Ltd. patent describes new aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.

Work at Bellbrook Labs LLC has led to the discovery of imidazolyl-alkoxyquinolin-2-amines acting as cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors.

Hotspot Therapeutics Inc. has identified new E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer.

New indazole pyridone compounds and their prodrugs have been patented by Bluejay Therapeutics Inc.